Reactions Weekly

, Volume 1151, Issue 1, pp 3–3 | Cite as

Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216

Media release
  • 12 Downloads

Keywords

Public Health Clinical Trial Hepatitis Marketing Fulminant Hepatitis 

REFERENCE

  1. 1.
    Astellas Pharma Inc.Adverse Event of FG-2216 for the Treatment of Anemia. Media Release: 7 May 2007. Available from: URL: http://www.astellas.com

Copyright information

© Adis International limited or Adis Data Information BV 2007

Personalised recommendations